A detailed history of Athyrium Capital Management, LP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Athyrium Capital Management, LP holds 1,256,411 shares of PBYI stock, worth $3.79 Million. This represents 100.0% of its overall portfolio holdings.

Number of Shares
1,256,411
Previous 1,256,411 -0.0%
Holding current value
$3.79 Million
Previous $4.1 Million 21.78%
% of portfolio
100.0%
Previous 100.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 16, 2024

SELL
$4.29 - $7.4 $2.3 Million - $3.96 Million
-535,703 Reduced 29.89%
1,256,411 $6.66 Million
Q1 2023

May 16, 2023

BUY
$2.21 - $4.82 $3.96 Million - $8.64 Million
1,792,114 New
1,792,114 $5.54 Million
Q1 2023

May 15, 2023

SELL
$2.21 - $4.82 $3.96 Million - $8.64 Million
-1,792,114 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.13 - $3.24 $3.82 Million - $5.81 Million
1,792,114 New
1,792,114 $5.16 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $138M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Athyrium Capital Management, LP Portfolio

Follow Athyrium Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Athyrium Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Athyrium Capital Management, LP with notifications on news.